- Home
- UFCS vs KALV Comparison
UFCS vs KALV Comparison
Compare UFCS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- KALV
- Stock Information
- Founded
- UFCS 1946
- KALV N/A
- Country
- UFCS United States
- KALV United States
- Employees
- UFCS N/A
- KALV N/A
- Industry
- UFCS Property-Casualty Insurers
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- KALV Health Care
- Exchange
- UFCS Nasdaq
- KALV Nasdaq
- Market Cap
- UFCS 666.1M
- KALV 651.3M
- IPO Year
- UFCS N/A
- KALV N/A
- Fundamental
- Price
- UFCS $27.97
- KALV $11.37
- Analyst Decision
- UFCS Buy
- KALV Strong Buy
- Analyst Count
- UFCS 2
- KALV 8
- Target Price
- UFCS $30.00
- KALV $24.83
- AVG Volume (30 Days)
- UFCS 95.1K
- KALV 497.6K
- Earning Date
- UFCS 05-06-2025
- KALV 07-10-2025
- Dividend Yield
- UFCS 2.28%
- KALV N/A
- EPS Growth
- UFCS N/A
- KALV N/A
- EPS
- UFCS 2.54
- KALV N/A
- Revenue
- UFCS $1,288,423,000.00
- KALV N/A
- Revenue This Year
- UFCS $13.54
- KALV N/A
- Revenue Next Year
- UFCS $9.84
- KALV N/A
- P/E Ratio
- UFCS $10.99
- KALV N/A
- Revenue Growth
- UFCS 14.59
- KALV N/A
- 52 Week Low
- UFCS $18.04
- KALV $7.30
- 52 Week High
- UFCS $31.70
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- UFCS 52.59
- KALV 40.61
- Support Level
- UFCS $26.71
- KALV $11.31
- Resistance Level
- UFCS $28.58
- KALV $12.71
- Average True Range (ATR)
- UFCS 0.88
- KALV 0.67
- MACD
- UFCS 0.04
- KALV -0.21
- Stochastic Oscillator
- UFCS 60.57
- KALV 5.58
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.